RxDoctor Payments Data

Brooke Edwards, MD

Urology · Crestview Hills, KYNPI 1770726382

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (44.1%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. It is spread thinly across 51 manufacturers, the largest accounting for just 22.5%. 2025 is the largest year on record at $12,456, 3.3 times the $3,763 reported in 2019. Among urology clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$44,557in general payments, 2019–2025

Across 545 payments — averaging $81.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$10K
  • Johnson & Johnson$9K
  • Pfizer$4K
  • Urogen Pharma, Inc.$3K
  • Teleflex LLC$2K
  • Neotract Inc.$2K
  • plus $15K from 45 others

What the payments were for

  • Consulting fees$16,75538%
  • Speaking & faculty fees$4,46010%
  • Travel & lodging$3,4628%
  • Food & beverage$19,66744%
  • Education$2120%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$44,557 in reported general payments places this provider in the 95th percentile of 139 urology providers in Kentucky.

See all urology providers in Kentucky

Medicare billing

Part B allowed, 2024
$106,031
Medicare patients
335
Services billed
4,632

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron97$55,232
GemtesaVibegron14$6,534
Tamsulosin Hcl211$2,142
Estradiol35$2,068
Trimethoprim19$873
Testosterone Cypionate12$747
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst33$596
Finasteride21$241
Cephalexin26$178
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim17$62
Ciprofloxacin Hcl11$56
Oxycodone Hcl16$41

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$1,268$55,23297 claims
Sumitomo Pharma America, Inc.Gemtesa$222$6,53414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 139 urology providers in Kentucky.

Other urology in Crestview Hills

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →